Syncromune®, Inc. to Present Phase 1 Data Highlighting Resolution of Bone Metastases in Metastatic Prostate Cancer Patients at the Society of Urological Oncology 26th Annual Meeting
The abstract, titled, “Effective resolution of bone metastases in patients with metastatic prostate cancer using SYNC-T Therapy SV-102,” was selected as one of the meeting’s “Top 30” submissions. This distinction recognizes Syncromune’s work as among the highest scoring abstracts of the year. As an honoree, the research will be featured in the SUO Top Abstract Tour which showcases exemplary contributions advancing the field of urologic oncology.
The data will be presented digitally as an electronic poster and highlights findings from the now-concluded Phase 1 study of SYNC-T Therapy SV-102 in metastatic prostate cancer, with a focus on radiographic resolution of bone metastases observed in patients who achieved complete responses. These results, presented alongside broader efficacy and safety data, underscore the potential of SYNC-T to address one of the most significant drivers of morbidity and mortality in advanced prostate cancer.
Presentation details:
Presenter: Gerald Andriole, M.D.
Title: Poster 175: Effective resolution of bone metastases in patients with metastatic prostate cancer using SYNC-T Therapy SV-102
Date/Time: Top 30 Abstract Tour, Dec. 4, 2025, 4:30-5:30 PM MDT
For more information about Syncromune®, Inc. please visit www.syncromune.com.
Source: Syncromune®, Inc. (2025). Syncromune®, Inc. to Present Phase 1 Data Highlighting Resolution of Bone Metastases in Metastatic Prostate Cancer Patients at the Society of Urological Oncology 26th Annual Meeting [Press release]. https://syncromune.com/2025/11/20/syncromune-inc-to-present-phase-1-data-highlighting-resolution-of-bone-metastases-in-metastatic-prostate-cancer-patients-at-the-society-of-urological-oncology-26th-annual-meeting/.